Multiple Sclerosis Organisations Commit to a Shared Global Research Strategy to Accelerate Cures for MS
Agreement seeks to coordinate resources on the highest potential research
TORONTO, June 14, 2023 (GLOBE NEWSWIRE) -- Multiple sclerosis organisations from Australia, Canada, Denmark, France, Germany, Italy, MS International Federation, Spain, U.K., and U.S. have jointly declare their collective commitment to a global research strategy to cure MS. There are multiple paths to MS cures and this coordination will effectively address knowledge gaps and avoid duplication to speed progress together.
Through the Global Research Strategy Framework the organisations will:
Complete a landscape analysis of MS research funding and infrastructure
Share national research plans and identify specific areas for collaboration and acceleration
Align individual and collective resources on the Global Research Framework
Create new joint initiatives to address strategic gaps
Report on progress together
"The MS community is diverse, and it spans far beyond Canada. Collaboration is key in making a world free of MS a reality," said Dr. Pamela Valentine, President and CEO, MS Canada. "Connecting the global MS community through our shared focus on a worldwide research strategy will help us reach pathways to cures for MS faster."
MS Organisations Endorsing this Statement:
Associazione Italiana Sclerosi Multipla (Italian MS Society)
Deutsche Multiple Sklerose Gesellschaft (Germany)
Esclerosis Múltiple España (Spain)
Fondation pour l'Aide à la Recherche sur la Sclérose En Plaques (France)
MS Australia
MS Canada
MS International Federation (Global)
MS Society UK
National MS Society (U.S.)
Scleroseforeningen (Danish MS Society)
About Pathways to Cures
Multiple sclerosis (MS) is a growing global health challenge affecting nearly 3 million people worldwide. Tremendous progress has been made in the understanding and treatment of MS over the last several decades, but cures remain elusive. Progress will be hastened by having a roadmap that describes the knowledge gaps, milestones, and research priorities leading to cures for everyone with MS.
The Pathways to Cures Roadmap was published in 2022 and includes carefully considered recommendations from leaders in MS research and clinical care, as well as people living with a lived experience with MS. The Roadmap has been endorsed by 30 leading MS patient and professional organisations across the globe.
Research breakthroughs leading to MS cures will require strategic investments in areas of high opportunity and increased multidisciplinary collaboration. The Pathways to Cures Roadmap is a comprehensive plan to achieve MS cures. It is a focal point to coordinate, innovate and optimize research investments.
Media Contact
Laila Namur Manager, Corporate Communications MS Canada
PhoreMost Ltd., a leading UK biopharmaceutical company unlocking the next generation of drug targets, today announced the introduction of GlueSEEKERtm. The new phenotypic screening platform expands the Company's capabilities in this emerging...
The National Comprehensive Cancer Network® (NCCN®)?a global nonprofit responsible for leading cancer treatment guidelines?is taking part in two events in Warsaw focused on advancing...
The 10th European Stroke Organization Congress (ESOC), held in Basel, Switzerland from May 15 to 17, 2024, showcased six studies on Sanbexin® (Edaravone and Dexborneol Concentrated Solution for Injection) and a new dosage form of sublingual tablets...
GC Biopharma (006280. KS) and Novel Pharma have announced that the U.S. FDA has cleared the investigational new drug (IND) application for their jointly developed MPSIIIA (Sanfilippo Syndrome Type A) treatment, GC1130A....
PathAI, a global leader in AI-powered pathology, today announced a new Early Access Program (EAP) to drive adoption of its AISightTM Image Management System (IMS) in Mainland Europe.1 Earlier in 2023, PathAI announced a similar program for...
Pheon Therapeutics (Pheon), a leading Antibody-Drug Conjugate (ADC) specialist developing next generation ADCs for a wide range of hard-to-treat cancers, today announces the completion of a $120m Series B financing to fund the development of its...